Regulation of Cas9 by viral proteins Tat and Rev for HIV-1 inactivation

Vergara-Mendoza, Moises; Gómez–Quiroz, Luis E.; Miranda-Labra, Roxana U.; Fuentes-Romero, Luis L.; Romero-Rodríguez, Dámaris P.; González-Ruiz, Jonathan; Hernández-Rizo, Sharik; Viveros-Rogel, Mónica

doi:10.1016/j.antiviral.2020.104856

Cited by 10 publications

(7 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on LAMP-Cas12a, Cas12a can detect HBV in 13-20 min [ 56 ]. The regulation of CRISPR-Cas9 genome editing on HIV-1 genome has become an effective tool for CRISPR-Cas9 system to treat HIV-1 [ 79 ]. Using a combination of isothermal amplification and CRISPR-Cas12a-mediated detection, HIV-1 genotypes were detected in 30 min under non-laboratory conditions [ 80 ].…”

Section: Application Of Crispr-cas System In Diagnosis and Treatment ...mentioning

confidence: 99%

The CRISPR-Cas system as a tool for diagnosing and treating infectious diseases

Lou

Wang

et al. 2022

Mol Biol Rep

View full text Add to dashboard Cite

Section: Application Of Crispr-cas System In Diagnosis and Treatment ...mentioning

confidence: 99%

The CRISPR-Cas system as a tool for diagnosing and treating infectious diseases

Lou

Wang

et al. 2022

Mol Biol Rep

View full text Add to dashboard Cite

“…However, shortly afterward, it became clear that NHEJ-mediated indels at the sgRNA target sites could generate viable HIV mutants that were resistant to re-cleavage by Cas9 and responsible for viral rebound later in the infection ( Ueda et al., 2016 ; Wang et al., 2016b ; Wang et al., 2016c ; Yoder and Bundschuh, 2016 ). In attempts to control escape mutant generation, multiplexing several sgRNAs targeting the same viral gene ( Wang et al., 2018 ; Ophinni et al., 2020 ; Vergara-Mendoza et al., 2020 ) and the deletion of differently-sized proviral segments using one gRNA specific to LTR and one directed to gag ( Kaminski et al., 2016 ; Wang et al., 2016a ; Yin et al., 2016 ; Yin et al., 2017 ; Wang et al., 2018 ), pol ( Yin et al., 2016 ; Yin et al., 2017 ), tat/rev ( Liao et al., 2015 ; Wang et al., 2016a ) or gag and pol simultaneously ( Yin et al., 2017 ; Wang et al., 2018 ) have been successfully tested. After NHEJ-mediated mutations that inhibit HIV replication, the infected cell may continue to produce certain viral proteins ( Kaminski et al., 2016 ; Yin et al., 2017 ) which will continue to exert pathogenic effects and deregulate immune responses ( Barillari and Ensoli, 2002 ; Witkowski and Verhasselt, 2013 ; Langer et al., 2019 ; Isaguliants et al., 2021 ).…”

Section: Gene Knockout Strategies In Hiv Therapymentioning

confidence: 99%

Application of CRISPR/Cas Genomic Editing Tools for HIV Therapy: Toward Precise Modifications and Multilevel Protection

Maslennikova

Mazurov

2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Although highly active antiretroviral therapy (HAART) can robustly control human immunodeficiency virus (HIV) infection, the existence of latent HIV in a form of proviral DNA integrated into the host genome makes the virus insensitive to HAART. This requires patients to adhere to HAART for a lifetime, often leading to drug toxicity or viral resistance to therapy. Current genome-editing technologies offer different strategies to reduce the latent HIV reservoir in the body. In this review, we systematize the research on CRISPR/Cas-based anti-HIV therapeutic methods, discuss problems related to viral escape and gene editing, and try to focus on the technologies that effectively and precisely introduce genetic modifications and confer strong resistance to HIV infection. Particularly, knock-in (KI) approaches, such as mature B cells engineered to produce broadly neutralizing antibodies, T cells expressing fusion inhibitory peptides in the context of inactivated viral coreceptors, or provirus excision using base editors, look very promising. Current and future advancements in the precision of CRISPR/Cas editing and its delivery will help extend its applicability to clinical HIV therapy.

show abstract

“…Several studies have focused on loss-of-function through CRISPR-Cas9-based gene knock-out strategies. Different types of virus genomes, including live viruses, 32 viral genomic DNA, 33 BAC DNA, 34 and integrated viral genes in cell genomes such as human immunodeficiency virus (HIV) 35 have been successfully modified via CRISPR-Cas9 system. The knock-out efficiency (number of plaques with deletion/total number of plaques) can reach 75% mediated by NHEJ repair mechanism for MDV in chicken embryo fibroblast cells 32 or 85% by HDR pathway for vaccinia virus.…”

Section: Loss-of-functionmentioning

confidence: 99%

Application of CRISPR-Cas9 Editing for Virus Engineering and the Development of Recombinant Viral Vaccines

et al. 2021

View full text Add to dashboard Cite

CRISPR-Cas technology, discovered originally as a bacterial defense system, has been extensively repurposed as a powerful tool for genome editing for multiple applications in biology. In the field of virology, CRISPR-Cas9 technology has been widely applied on genetic recombination and engineering of genomes of various viruses to ask some fundamental questions of virus-host interactions. Its high efficiency, specificity, versatility, and low cost have also provided great inspirations and hope in the field of vaccinology to solve a series of bottleneck problems in the development of recombinant viral vaccines. This review highlights the applications of CRISPR editing in the technological advances compared to the traditional approaches used for the construction of recombinant viral vaccines and vectors, the main factors affecting their application, and the challenges that need to be overcome for further streamlining their effective usage in the prevention and control of diseases. Factors affecting efficiency, target specificity and fidelity of CRISPR-Cas editing in the context of viral genome editing and development of recombinant vaccines are also discussed.

show abstract

Regulation of Cas9 by viral proteins Tat and Rev for HIV-1 inactivation

Cited by 10 publications

References 45 publications

The CRISPR-Cas system as a tool for diagnosing and treating infectious diseases

The CRISPR-Cas system as a tool for diagnosing and treating infectious diseases

Application of CRISPR/Cas Genomic Editing Tools for HIV Therapy: Toward Precise Modifications and Multilevel Protection

Application of CRISPR-Cas9 Editing for Virus Engineering and the Development of Recombinant Viral Vaccines

Contact Info

Product

Resources

About